Travere Therapeutics Inc. (TVTX) is gearing up for a crucial milestone as it finalizes preparations to be ready for full approval of one of its drugs next month.
The drug in focus is Filspari, which was granted accelerated approval by the FDA to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression in February 2023.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com